Swiss pharma giant Roche and US biotech Alnylam have opted to take zilebesiran, a RNAi therapeutic, into a Phase III ...

Independent French drugmaker Servier and US oncology company IDEAYA Biosciences have announced an exclusive license agreement ...

Poland’s clinical-stage drug cancer focused developer Ryvu Therapeutics is entering a strategic agreement with Germany’s ...

Shares of California based Ionis Pharmaceuticals shot up 17.8% to $50.23 in pre-market trading today, after it announced ...

China is leveraging its vast resources to become a top global supplier of cost effective "best-in-class" treatments, a shift ...

Bispecific (bs) antibody drug conjugates (ADCs) are an emerging therapeutic approach that presents advantages over ...

Canadian clinical-stage biotech Zymeworks today announced its decision to voluntarily discontinue clinical development of ZW171, a T cell engager designed to target gynecological, thoracic, and ...

Tuesday brought a major announcement from French contract development and manufacturing organization (CDMO) Naobios, Austria’s Nuvonis, a biotech providing cell banks for the production of vaccines ...

Danish biotech Genmab (Nasdaq: GMAB) has appointed Matt Kiely as the general manager for the UK as the company expands its presence in Europe to bring its innovative antibody-based medicines to more ...

European lawmakers have stepped up efforts to overhaul the EU’s Critical Medicines Act. A draft report for the public health committee reveals a push for stronger manufacturing competitiveness, ...

Poland-headquartered Polpharma Biologics today announced that it has signed licensing agreements with MS Pharma, a leading biosimilar production and distribution company in the Middle East and North ...

Global regulators have been active over the past week, with a mix of policy updates, labeling changes, and priority review initiatives shaping the drug development landscape. From Washington to Tokyo, ...